109 related articles for article (PubMed ID: 30300203)
1. 18F-DCFPyL PET/CT in Oncocytoma.
Li J; Xu R; Kim CK; Bénard F; Kapoor A; Bauman G; Zukotynski KA
Clin Nucl Med; 2018 Dec; 43(12):921-924. PubMed ID: 30300203
[TBL] [Abstract][Full Text] [Related]
2. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
3. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
4. Intraindividual Comparison of
Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
[TBL] [Abstract][Full Text] [Related]
5. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
6. Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Broos WAM; Kocken M; van der Zant FM; Knol RJJ; Wondergem M
Clin Nucl Med; 2018 Feb; 43(2):120-122. PubMed ID: 29261618
[TBL] [Abstract][Full Text] [Related]
7. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
8. Combined model-based and patient-specific dosimetry for
Plyku D; Mena E; Rowe SP; Lodge MA; Szabo Z; Cho SY; Pomper MG; Sgouros G; Hobbs RF
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):989-998. PubMed ID: 29460025
[TBL] [Abstract][Full Text] [Related]
9.
Wondergem M; van der Zant FM; Knol RJJ; Lazarenko SV; Pruim J; de Jong IJ
J Nucl Med; 2017 Nov; 58(11):1797-1804. PubMed ID: 28450569
[TBL] [Abstract][Full Text] [Related]
10. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted
Meyer AR; Carducci MA; Denmeade SR; Markowski MC; Pomper MG; Pierorazio PM; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2019 Aug; 33(8):617-623. PubMed ID: 31147927
[TBL] [Abstract][Full Text] [Related]
11. Low levels of PSMA expression limit the utility of
Campbell SP; Baras AS; Ball MW; Kates M; Hahn NM; Bivalacqua TJ; Johnson MH; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2018 Jan; 32(1):69-74. PubMed ID: 29067547
[TBL] [Abstract][Full Text] [Related]
12. High 18Fluor-DCFPyL Uptake in Adrenal Adenomas.
Peper JGK; Srbljin S; van der Zant FM; Knol RJJ; Wondergem M
Clin Nucl Med; 2017 Nov; 42(11):862-864. PubMed ID: 28825951
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Local Recurrence Detected With Both
Gorin MA; Pienta KJ; Pomper MG; Rowe SP
Urology; 2017 Sep; 107():e9-e10. PubMed ID: 28641974
[TBL] [Abstract][Full Text] [Related]
14. PSMA-Targeted
Gorin MA; Rowe SP; Hooper JE; Kates M; Hammers HJ; Szabo Z; Pomper MG; Allaf ME
Eur Urol; 2017 Jan; 71(1):145-146. PubMed ID: 27363386
[No Abstract] [Full Text] [Related]
15. Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.
Rowe SP; Gorin MA; Hammers HJ; Pomper MG; Allaf ME; Javadi MS
Clin Nucl Med; 2016 Jan; 41(1):83-5. PubMed ID: 26402128
[TBL] [Abstract][Full Text] [Related]
16.
Wondergem M; van der Zant FM; Broos WAM; Roeleveld TA; Donker R; Ten Oever D; Geenen RWF; Knol RJJ
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):521-531. PubMed ID: 32719916
[TBL] [Abstract][Full Text] [Related]
17. Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT.
Chaussé G; Laufer J; Abikhzer G; Probst S
Clin Nucl Med; 2019 Mar; 44(3):255-256. PubMed ID: 30589670
[TBL] [Abstract][Full Text] [Related]
18. Oncocytoma: A Differential Consideration for an Incidentally Detected FDG-Avid Renal Mass on PET/CT.
Smith CJ; Wang MX; Feely M; Otto B; Grajo JR
J Radiol Case Rep; 2017 May; 11(5):27-33. PubMed ID: 29299091
[TBL] [Abstract][Full Text] [Related]
19. PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?
Rowe SP; Mana-Ay M; Javadi MS; Szabo Z; Leal JP; Pomper MG; Pienta KJ; Ross AE; Gorin MA
Clin Genitourin Cancer; 2016 Feb; 14(1):e115-8. PubMed ID: 26603549
[No Abstract] [Full Text] [Related]
20. Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations.
Zukotynski KA; Valliant J; Bénard F; Rowe SP; Kim CK; Pomper MG; Cho SY
Clin Nucl Med; 2018 Mar; 43(3):213-216. PubMed ID: 29356735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
